Do analysts prefer MJN or WEED?

Canopy Growth has a consensus target price of C$1.88, suggesting a potential upside of 38.89%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than Cronos Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger valuation and earnings, MJN or WEED?

Cronos Group has higher earnings, but lower revenue than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group N/A N/A N/A N/A N/A Canopy Growth C$293.63M 2.07 -C$1.05B -C$0.67 N/A

Which has better earnings & valuation, WEED or CRON?

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canopy Growth C$293.63M 2.07 -C$1.05B -C$0.67 N/A Cronos Group C$179.09M 9.17 -C$32.78M C$0.19 23.47

Do analysts rate CARA or WEED?

Canopy Growth has a consensus price target of C$1.88, suggesting a potential upside of 38.89%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than Cara Operations. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Operations 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger valuation & earnings, CARA or WEED?

Cara Operations has higher earnings, but lower revenue than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cara Operations N/A N/A N/A N/A N/A Canopy Growth C$293.63M 2.07 -C$1.05B -C$0.67 N/A

Canopy Growth (WEED) Competitors

C$1.35 0.00 (0.00%)

As of 09/3/2026 04:00 PM Eastern

Compare

WEED vs. MJN, CRON, CARA, DB, and DHT.UN

Should you buy Canopy Growth stock or one of its competitors? Canopy Growth's main competitors and comparable companies include Cronos Group (MJN), Cronos Group (CRON), Cara Operations (CARA), Decibel Cannabis (DB), and DRI Healthcare Trust (DHT.UN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Canopy Growth compare to Cronos Group?

Cronos Group (CVE:MJN) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

4.5% of Canopy Growth shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cronos Group had 1 more articles in the media than Canopy Growth. MarketBeat recorded 1 mentions for Cronos Group and 0 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.76 beat Cronos Group's score of 0.51 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
Cronos Group	Positive
Canopy Growth	Positive

Cronos Group has higher earnings, but lower revenue than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	N/A	N/A	N/A	N/A	N/A
Canopy Growth	C$293.63M	2.07	-C$1.05B	-C$0.67	N/A

Cronos Group has a net margin of 0.00% compared to Canopy Growth's net margin of -73.95%. Cronos Group's return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	N/A	N/A	N/A
Canopy Growth	-73.95%	-29.85%	-3.83%

Canopy Growth has a consensus target price of C$1.88, suggesting a potential upside of 38.89%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Canopy Growth beats Cronos Group on 7 of the 11 factors compared between the two stocks.

How does Canopy Growth compare to Cronos Group?

Canopy Growth (TSE:WEED) and Cronos Group (TSE:CRON) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

4.5% of Canopy Growth shares are owned by institutional investors. Comparatively, 4.4% of Cronos Group shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Comparatively, 46.4% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Canopy Growth's average media sentiment score of 0.76 beat Cronos Group's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Overall Sentiment
Canopy Growth	Positive
Cronos Group	Neutral

Canopy Growth presently has a consensus target price of C$1.88, suggesting a potential upside of 38.89%. Cronos Group has a consensus target price of C$4.92, suggesting a potential upside of 10.24%. Given Canopy Growth's higher probable upside, equities analysts plainly believe Canopy Growth is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Canopy Growth has a beta of 1.634762, indicating that its stock price is 63% more volatile than the broader market. Comparatively, Cronos Group has a beta of 1.13355, indicating that its stock price is 13% more volatile than the broader market.

Cronos Group has a net margin of 38.95% compared to Canopy Growth's net margin of -73.95%. Cronos Group's return on equity of 6.46% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-73.95%	-29.85%	-3.83%
Cronos Group	38.95%	6.46%	-3.73%

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$293.63M	2.07	-C$1.05B	-C$0.67	N/A
Cronos Group	C$179.09M	9.17	-C$32.78M	C$0.19	23.47

Summary

Cronos Group beats Canopy Growth on 10 of the 15 factors compared between the two stocks.

How does Canopy Growth compare to Cara Operations?

Cara Operations (TSE:CARA) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Cara Operations has higher earnings, but lower revenue than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cara Operations	N/A	N/A	N/A	N/A	N/A
Canopy Growth	C$293.63M	2.07	-C$1.05B	-C$0.67	N/A

4.5% of Canopy Growth shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Canopy Growth has a consensus price target of C$1.88, suggesting a potential upside of 38.89%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Canopy Growth is more favorable than Cara Operations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cara Operations	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Canopy Growth's average media sentiment score of 0.76 beat Cara Operations' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
Cara Operations	Neutral
Canopy Growth	Positive

Cara Operations has a net margin of 0.00% compared to Canopy Growth's net margin of -73.95%. Cara Operations' return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cara Operations	N/A	N/A	N/A
Canopy Growth	-73.95%	-29.85%	-3.83%

Summary

Canopy Growth beats Cara Operations on 7 of the 10 factors compared between the two stocks.

How does Canopy Growth compare to Decibel Cannabis?

Decibel Cannabis (CVE:DB) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Decibel Cannabis had 1 more articles in the media than Canopy Growth. MarketBeat recorded 1 mentions for Decibel Cannabis and 0 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.76 beat Decibel Cannabis' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
Decibel Cannabis	Neutral
Canopy Growth	Positive

Decibel Cannabis has a net margin of -3.78% compared to Canopy Growth's net margin of -73.95%. Decibel Cannabis' return on equity of -1.05% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decibel Cannabis	-3.78%	-1.05%	3.04%
Canopy Growth	-73.95%	-29.85%	-3.83%

Decibel Cannabis currently has a consensus target price of C$0.18, indicating a potential downside of 90.33%. Canopy Growth has a consensus target price of C$1.88, indicating a potential upside of 38.89%. Given Canopy Growth's higher probable upside, analysts plainly believe Canopy Growth is more favorable than Decibel Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decibel Cannabis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Decibel Cannabis has higher earnings, but lower revenue than Canopy Growth. Decibel Cannabis is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decibel Cannabis	C$127.08M	0.55	-C$1.03M	-C$0.15	N/A
Canopy Growth	C$293.63M	2.07	-C$1.05B	-C$0.67	N/A

0.0% of Decibel Cannabis shares are owned by institutional investors. Comparatively, 4.5% of Canopy Growth shares are owned by institutional investors. 1.1% of Decibel Cannabis shares are owned by company insiders. Comparatively, 0.2% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Decibel Cannabis has a beta of 0.321627, meaning that its share price is 68% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 1.634762, meaning that its share price is 63% more volatile than the broader market.

Summary

Decibel Cannabis beats Canopy Growth on 9 of the 17 factors compared between the two stocks.

How does Canopy Growth compare to DRI Healthcare Trust?

Canopy Growth (TSE:WEED) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Canopy Growth has a beta of 1.634762, suggesting that its share price is 63% more volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.365327, suggesting that its share price is 63% less volatile than the broader market.

In the previous week, DRI Healthcare Trust had 2 more articles in the media than Canopy Growth. MarketBeat recorded 2 mentions for DRI Healthcare Trust and 0 mentions for Canopy Growth. DRI Healthcare Trust's average media sentiment score of 1.49 beat Canopy Growth's score of 0.76 indicating that DRI Healthcare Trust is being referred to more favorably in the news media.

Company	Overall Sentiment
Canopy Growth	Positive
DRI Healthcare Trust	Positive

Canopy Growth presently has a consensus price target of C$1.88, indicating a potential upside of 38.89%. DRI Healthcare Trust has a consensus price target of C$25.20, indicating a potential upside of 44.33%. Given DRI Healthcare Trust's stronger consensus rating and higher possible upside, analysts clearly believe DRI Healthcare Trust is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

4.5% of Canopy Growth shares are owned by institutional investors. Comparatively, 0.8% of DRI Healthcare Trust shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Comparatively, 0.1% of DRI Healthcare Trust shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

DRI Healthcare Trust has a net margin of 5.02% compared to Canopy Growth's net margin of -73.95%. DRI Healthcare Trust's return on equity of 2.06% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-73.95%	-29.85%	-3.83%
DRI Healthcare Trust	5.02%	2.06%	4.22%

DRI Healthcare Trust has lower revenue, but higher earnings than Canopy Growth. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$293.63M	2.07	-C$1.05B	-C$0.67	N/A
DRI Healthcare Trust	C$172.34M	5.57	C$9.73M	-C$0.80	N/A

Summary

DRI Healthcare Trust beats Canopy Growth on 11 of the 17 factors compared between the two stocks.

Get Canopy Growth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WEED vs. The Competition

Export

Metric	Canopy Growth	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$606.55M	C$12.25B	C$7.26B	C$12.57B
Dividend Yield	4.80%	2.59%	2.53%	6.25%
P/E Ratio	-2.01	787.27	273.29	39.47
Price / Sales	2.07	753.78	613.45	9.82
Price / Cash	1.63	94.80	77.82	82.29
Price / Book	0.83	12.33	12.89	4.71
Net Income	-C$1.05B	C$2.82B	C$3.47B	C$299.09M
7 Day Performance	-3.57%	2.59%	0.60%	-0.31%
1 Month Performance	2.27%	6.95%	5.73%	3.12%
1 Year Performance	-29.32%	9.45%	25.35%	28.73%

Canopy Growth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
WEED Canopy Growth	2.0043 of 5 stars	C$1.35 flat	C$1.88 +38.9%	-29.7%	C$606.55M	C$293.63M	N/A	2,700
MJN Cronos Group	N/A	C$12.15 -1.9%	N/A	+0.0%	C$1.73B	N/A	N/A	7,600
CRON Cronos Group	1.8139 of 5 stars	C$4.68 +0.4%	C$4.92 +5.1%	+28.2%	C$1.72B	C$179.09M	24.63	450
CARA Cara Operations	N/A	N/A	N/A	N/A	C$1.62B	N/A	N/A	80
DB Decibel Cannabis	0.7723 of 5 stars	C$1.93 +2.9%	C$0.18 -90.9%	+1,292.3%	C$1.11B	C$127.08M	N/A	83,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:WEED) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Canopy Growth (WEED) Competitors

WEED vs. MJN, CRON, CARA, DB, and DHT.UN

How does Canopy Growth compare to Cronos Group?

Summary

How does Canopy Growth compare to Cronos Group?

Summary

How does Canopy Growth compare to Cara Operations?

Summary

How does Canopy Growth compare to Decibel Cannabis?

Summary

How does Canopy Growth compare to DRI Healthcare Trust?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WEED vs. The Competition

Canopy Growth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Canopy Growth (WEED) Competitors

WEED vs. MJN, CRON, CARA, DB, and DHT.UN

How does Canopy Growth compare to Cronos Group?

Do insiders & institutionals hold more shares of MJN or WEED?

Does the media favor MJN or WEED?

Which has stronger valuation and earnings, MJN or WEED?

Is MJN or WEED more profitable?

Do analysts prefer MJN or WEED?

Summary

How does Canopy Growth compare to Cronos Group?

Do insiders and institutionals hold more shares of WEED or CRON?

Does the media favor WEED or CRON?

Do analysts rate WEED or CRON?

Which has more risk and volatility, WEED or CRON?

Is WEED or CRON more profitable?

Which has better earnings & valuation, WEED or CRON?

Summary

How does Canopy Growth compare to Cara Operations?

Which has stronger valuation & earnings, CARA or WEED?

Do insiders & institutionals have more ownership in CARA or WEED?

Do analysts rate CARA or WEED?

Does the media refer more to CARA or WEED?

Is CARA or WEED more profitable?

Summary

How does Canopy Growth compare to Decibel Cannabis?

Does the media prefer DB or WEED?

Is DB or WEED more profitable?

Do analysts rate DB or WEED?

Which has higher earnings & valuation, DB or WEED?

Do insiders and institutionals believe in DB or WEED?

Which has more risk and volatility, DB or WEED?

Summary

How does Canopy Growth compare to DRI Healthcare Trust?

Which has more volatility & risk, WEED or DHT.UN?

Does the media favor WEED or DHT.UN?

Do analysts prefer WEED or DHT.UN?

Do insiders & institutionals believe in WEED or DHT.UN?

Is WEED or DHT.UN more profitable?

Which has stronger earnings & valuation, WEED or DHT.UN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WEED vs. The Competition

Canopy Growth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools